Reports

Stephan Emmerth

Stephan Emmerth

PhD | Director Therapeutic Innovation and BaseLaunch


Tel. +41 61 295 50 17

stephan.notexisting@nodomain.comemmerth@baselarea.notexisting@nodomain.comswiss
report Life Sciences
Hans-Peter Gerber, Vice President, Pfizer Worldwide Research & Development. (Img: Terrapinn)

Hans-Peter Gerber, Vice President, Pfizer Worldwide Research & Development. (Img: Terrapinn)

06.07.2016

Join global leaders such as Novartis, Roche and Pfizer this November

Once again the European Antibody Congress is returning to Basel to celebrate scientific innovation both locally and worldwide.

This year both Novartis and Pfizer will be giving the keynote addresses at the 12th annual European Antibody Congress, taking place 14-16th November 2016 at the Basel Congress Centre. Dr Sonia Quaratino from Novartis Institutes for Biomedical Research will be joining the event to discuss new developments within their clinical programmes. Dr Hans-Peter Gerber, from Pfizer Worldwide Research and Development will be addressing the audience on combining antibody-drug conjugates and immune-mediated cancer therapies.

The congress will also be joined by other big names from influential companies such as Roche, Genentech, Bayer Pharma, AbbVie and MedImmune to name a few.

Ground breaking new research
This year, as well as the industry giants, the congress also has some very promising research presented by up and coming academics. The European Antibody Congress 2016 will have Dr Wouter Verdurmen from Radboudumc, talk about his incredible alternative protein scaffold, aiming to allow proteins to target within the cytosol. Dr Aurélien Lathuiliére from the Hôpitaux Universitaires de Genève will be discussing with the 500 strong audience the concept of his ground breaking anti-amyloid beta antibody delivery using ECT for the prevention of Alzheimer’s disease. The congress will also be joined by Guillaume Brachet, University of Tours, who will be bringing a powerful insight into Brentuximab vedotin, and giving an update on its drug loading, aggregation and Fc neonatal receptor binding.

This new research, complemented by the big industry names such as Janssen, Amgen, Merck Serono, Immunogen and Seattle Genetics, will ensure that the European Antibody Congress 2016 is a truly well-rounded and thought provoking Event.

World Immunotherapy Congress
This year the Inaugural World Immunotherapy Congress 2016 is also being launched, to compliment the content covered in the European Antibody Congress. With big names from Memorial Sloane Kettering Centre, Roche, Novartis, Juno Therapeutics, and Cellectis, this is a very positive addition to the co-location and will also be joined with the 5th annual World Biosimilar Congress and the 4th annual HPAPI World Congress in Basel this November.

Technology Showcase as opportunity for innovators
The congress will also see the return of the successful Platform Technology Showcase which debuted last year, providing an opportunity for innovators to pitch their technology and ideas to the audience of international investors, big pharma companies and biotechs. Following the successful launch last year, the hope is to bring even more innovative and new technology to this audience, with companies such as Nanotemper already signed up to present.

Exclusive benefits for i-net subscribers
There are still a few opportunities for innovators from Basel to join the platform technology showcase. Contact the organisers to find out more.

Any questions: Contact Project Manager Derek Cavanagh on +44 207 092 1297 or email notexisting@nodomain.comcavanagh@terrapinn.notexisting@nodomain.comcom" target="_blank">derek.notexisting@nodomain.comcavanagh@terrapinn.notexisting@nodomain.comcom

Find out more by downloading the brochure

Article courtesy of European Antibody Congress

Categories

Life Sciences
Cookies

BaselArea.swiss uses cookies to ensure you get the best service on our website.
By continuing to browse the site, you are agreeing to the use of cookies.

Ok